Antibody and lectin target podoplanin to inhibit oral squamous carcinoma cell migration and viability by distinct mechanisms
Metrics: PDF 1144 views | HTML 3786 views | ?
Jhon A. Ochoa-Alvarez1, Harini Krishnan1, John G. Pastorino1, Evan Nevel1, David Kephart1, Joseph J. Lee1, Edward P. Retzbach1, Yongquan Shen1, Mahnaz Fatahzadeh2, Soly Baredes3, Evelyne Kalyoussef3, Masaru Honma4, Martin E. Adelson5, Mika K. Kaneko6, Yukinari Kato6, Mary Ann Young1, Lisa Deluca-Rapone1, Alan J. Shienbaum1, Kingsley Yin1, Lasse D. Jensen7 and Gary S. Goldberg1
1 Departments of Molecular Biology, Cell Biology, and Pathology, School of Osteopathic Medicine, Rowan University, Stratford, NJ, USA
2 Department of Diagnostic Sciences, Rutgers School of Dental Medicine, Newark, NJ, USA
3 Department of Otolaryngology - Head and Neck Surgery, Rutgers New Jersey Medical School, Newark, NJ, USA
4 Department of Dermatology, Asahikawa Medical University, Midorigaoka-Higashi, Asahikawa, Japan
5 Medical Diagnostic Laboratories, Hamilton, NJ, USA
6 Department of Regional Innovation, Tohoku University Graduate School of Medicine, Seiryo-machi, Aoba-ku, Sendai, Miyagi, Japan
7 Department of Medical and Health Sciences, Linköping University, Lasarettsgatan, Ingång, Linköping, Sweden
Gary S. Goldberg, email:
Keywords: podoplanin, cancer, cell migration, receptor, lectin
Received: October 13, 2014 Accepted: February 04, 2015 Published: March 10, 2015
Podoplanin (PDPN) is a unique transmembrane receptor that promotes tumor cell motility. Indeed, PDPN may serve as a chemotherapeutic target for primary and metastatic cancer cells, particularly oral squamous cell carcinoma (OSCC) cells that cause most oral cancers. Here, we studied how a monoclonal antibody (NZ-1) and lectin (MASL) that target PDPN affect human OSCC cell motility and viability. Both reagents inhibited the migration of PDPN expressing OSCC cells at nanomolar concentrations before inhibiting cell viability at micromolar concentrations. In addition, both reagents induced mitochondrial membrane permeability transition to kill OSCC cells that express PDPN by caspase independent nonapoptotic necrosis. Furthermore, MASL displayed a surprisingly robust ability to target PDPN on OSCC cells within minutes of exposure, and significantly inhibited human OSCC dissemination in zebrafish embryos. Moreover, we report that human OSCC cells formed tumors that expressed PDPN in mice, and induced PDPN expression in infiltrating host murine cancer associated fibroblasts. Taken together, these data suggest that antibodies and lectins may be utilized to combat OSCC and other cancers that express PDPN.
Approximately 300,000 new cases of oral cancer are diagnosed each year, causing over 120,000 deaths worldwide [1, 2]. Greater than 90% of these cancers are oral squamous cell carcinomas (OSCC) that proceed from hyperplasia to dysplasia, carcinoma in situ, and invasive carcinoma [3, 4]. Patients with early (stage I or II) OSCC are generally treated with surgery and radiation therapy, yielding 5-year survival rates between 70% and 95% [5, 6]. However, patients with more advanced OSCC (stage III or IV) have much lower 5 year survival rates, ranging from 26% to 53% . Cancer recurrence is found in up to 76% of patients treated with surgery and radiation, and many of these metastasize to distant sites [7, 8]. In addition, these surgeries and radiation treatments can be disfiguring and cause acute patient discomfort (e.g. oral mucositis), as well as permanent sequelae [6, 9].
Oral cancer does not respond well to standard chemotherapeutic agents. Taxanes, anthracyclines, platinums, and antimetabolites have been used as adjuvant oral cancer therapy for several decades . For example, methotrexate, cisplatin, carboplatin, 5-fluorouracil, paclitaxel, and docetaxel are commonly used to treat advanced OSCC . In general, these agents have shown significant toxicity and have had little effect on outcomes [10, 11]. Collateral damage to dividing cells can cause mucositis, renal dysfunction, neurotoxicity, and haemotologic toxicities that can be debilitating and even deadly [10, 12]. In fact, over 40 years of work and clinical trials with cytotoxic chemotherapy agents have not considerably increased survival rates or quality of life for oral cancer patients [7, 11]. New treatments are clearly needed to improve outcomes in this patient population.
Targeting specific extracellular receptors can lead to successful cancer therapies. These targeted therapies include tyrosine kinase blockers that inhibit the activities of EGFR receptors (e.g. cetuximab, lapatinib) [13, 14], as well as monoclonal antibodies that target the HER2/NEU/ERB2 receptor (e.g. trastuzumab) or VEGFR2/KDR ligands (e.g. bevacizumab) [15, 16]. Indeed, cetuximab has shown promising results in clinical trials involving OSCC [17, 18]. Undoubtedly, extracellular receptors are valid targets for the treatment of human cancer.
OSCC cells present podoplanin (PDPN) as a functionally relevant biomarker and potential chemotherapeutic target. OSCC and premalignant lesions often exhibit polymorphisms in cyclin D1, and inactivation of tumor suppressors including p53, p16 and p14 [19-21]. Increased expression of tumor promoters including TIMPs, c-myc, cyclin D1, TGF-α, EGFR, and PDPN are also often seen in these lesions [19, 22-24]. Taken together, reports indicate that PDPN expression is notably increased in over 30% of pre-malignant oral lesions and in over 60% of oral cancers. Moreover, PDPN expression correlates with clinicopathological factors. About 50% of T1 and T2 primary tumors display elevated PDPN expression, and this number increases to about 75% for those at stages T3 and T4. In addition, over 70% of primary OSCC tumors with cervical lymph node metastases express elevated levels of PDPN [5, 25-28]. Clinical studies also indicate that 5-year overall survival (OS) rates continuously decrease from 93% for patients with weak podoplanin expression, to 47% for patients with moderate expression, to 23% for patients with high levels of podoplanin expression [5, 29]. OSCC lethality also correlates with PDPN expression, with undetectable, weak, moderate, and high PDPN expression resulting in 100%, 93%, 70%, and 37% 5-year disease-specific survival (DSS) rates, respectively . PDPN promotes OSCC cell motility [30, 31] to drive tumor invasion and metastasis that cause most oral cancer deaths [7, 32, 33].
PDPN is a transmembrane mucin-like protein that augments tumor cell invasion. PDPN expression is induced by tumor promoters including TPA, RAS, and Src [34-36]. The Src tyrosine kinase utilizes the focal adhesion adaptor protein Cas/BCAR to induce PDPN expression in order to promote tumor cell motility . PDPN regulates the activities of Rho, ezrin, and other proteins linked to the actin cytoskeleton to mediate filopodia formation, cell motility, invasion, and metastasis [37, 38]. Indeed, PDPN expression enhances the motility and invasion of several transformed cell types including mammary carcinoma [37, 39], glioma , and OSCC [30, 31]. PDPN is also located on lymphatic endothelial cells and cancer associated fibroblasts which can augment tumor invasion and metastasis [41, 42].
PDPN is found at the invasive front of many tumors, which is consistent with its role in promoting invasion [37, 39]. As discussed above, PDPN expression is strongly induced in most oral cancers [4, 5, 27, 28]. The bulk of the PDPN protein, about 150 amino acids, lies outside of the cell and could serve as an ideal target to combat cancer growth and progression [37, 43]. For example, antibodies against PDPN can inhibit the growth and metastasis of tumor cells that express PDPN in mice [44-47].
While antibodies may offer significant targeting specificity, they cannot be administered orally, and may not possess intrinsic pharmaceutical effects on tumor cell growth and migration seen with orally available lectins [48-50]. The extracellular domain of PDPN is O-glycosylated with sialic acid α2,3 linked to galactose . PDPN is activated by endogenous lectins that bind to these extracellular carbohydrate moieties [51, 52] to induce tumor cell motility and metastasis [39, 53, 54]. Thus, blocking this interaction between PDPN and its ligands should inhibit malignant progression. For instance, compounds blocking the action of galectins, which activate mucin receptors, can inhibit tumor cell metastasis [55, 56]. Although some lectins may nonspecifically bind to many glycoproteins, Maackia amurensis seed lectin (MASL) can precisely target specific glycoproteins expressed by human cells [57, 58]. In fact, MASL, which has a high affinity for O-linked carbohydrate chains containing sialic acid [59, 60], targets PDPN in order to inhibit tumor cell growth and motility at nanomolar concentrations .
Here, we compare the effects of anti-PDPN antibody and MASL on OSCC cell motility and growth. These results indicate that both reagents affect OSCC cells at similar concentrations and by comparable mechanisms. However, MASL presents very efficient targeting dynamics and an advantage of oral administration.
PDPN expression correlates with OSCC cell motility
As described above, PDPN is a functionally relevant biomarker and potential chemotherapeutic target expressed by malignant OSCC cells. Immunohistochemistry found PDPN expression in OSCC specimens from oral cancer patients, as well as from a patient with leukoplakia as shown in Figure 1a and Table 1. Immunohistochemistry also detected PDPN expression in cultured OSCC cells as shown in Figure 1b and Table 2.
Table 1: Patient samples. Diagnosis, lesion sites, patient sex, age, PDPN expression, and HPV status are shown.
Table 2: OSCC cell lines. Diagnosis, lesion sites, patient sex, age, PDPN expression, and HPV status are shown.
Since PDPN can promote cell migration, we sought to evaluate the relationship between its expression with OSCC cell motility. PDPN expression and cell migration were examined in a panel of cell lines generated from oral cancer patients presented in Table 2. Western blot analysis found that these HSC-2, HSC-4, and HSQ-89 cells all expressed PDPN, but at decreasing levels, respectively (Figure 2a and 2b). These data are consistent with immunohistochemistry results shown in Figure 1b and Table 2. Moreover, as shown in Figure 2c, PDPN expression levels correlated with the ability of these cells to migrate as measured by wound healing assays. These data are consistent with reports indicating that PDPN expression can increase cell migration.
Figure 1: PDPN expression in OSCC cells. PDPN expression in OSCC cells was examined by immunohistochemistry. (a) Specimens from oral cancer patients (bar = 40 microns). (b) Cultured OSCC cells (bar = 100 microns).
Figure 2: Pdpn expression correlates with OSCC cell motility. (a) PDPN and GAPDH were detected by Western blotting of protein (20 µg per lane) from HSC-2, HSC-4, and HSQ-89 OSCC cells. (b) PDPN expression was quantitated by image densitometry and shown as mean+SEM (n=2). (c) Cell migration was evaluated by wound healing and quantitated as the number of cells that migrated into a 200 x 300 micron area in the center of the wound at 18 hours (mean+SEM, n=5). Single, double, and quadruple asterisks indicate p<0.05, p<0.01, and p<0.0001 compared to HSC-2 cells, respectively.
Agents that target PDPN inhibit OSCC cell motility and growth in a PDPN dependent manner
Previous studies indicate that antibodies and lectins can be used to target PDPN in order to inhibit tumor cell migration and growth. These reagents are exemplified by NZ-1 antibody and MASL lectin [45, 61-64]. We utilized HSC-2, HSC-4, and HSQ-89 cells to evaluate the effects of NZ-1 and MASL on cell migration. As shown in Figure 3a and Supplemental Figure 1, MASL and NZ-1 both inhibited OSCC cell migration at nanomolar concentrations. Migration of HSC-2 cells, which expressed the highest levels of PDPN, was effectively inhibited by 770 nM NZ-1 and MASL. HSC-4 cell migration was effectively inhibited by 770 nM NZ-1, but required 1540 nM MASL to achieve similar results. Neither MASL nor NZ-1 showed significant effects on HSQ-89 cells, which exhibited only nominal migration and PDPN expression levels. These data indicate that NZ-1 and MASL both inhibit cell migration in a manner that correlates with PDPN expression.
In addition to inhibiting migration, MASL and NZ-1 both suppressed OSCC cell growth as shown in Figure 3b and Supplemental Figure 2. These reagents inhibited the growth of HSC-2 cells by over 80% and HSC-4 cells by over 60% at a 2.3 µM concentration. HSQ-89 cells were less sensitive to these reagents, with 2.3 µM NZ-1 inhibiting growth by about 50%, and MASL by about 15%. Since HSQ-89 cells exhibited only nominal migration and PDPN expression levels, they may not have been as effectively targeted by these reagents. Taken together, these data indicate that NZ-1 and MASL inhibited cell migration prior to suppressing cell growth. Moreover, both reagents preferentially targeted cells that express PDPN, and MASL exhibited specificity at least as strong as the NZ-1 monoclonal antibody.
RhoA and Rac1 GTPase activity has been implicated in PDPN induced cell migration [65-67]. Therefore, we sought to determine if reagents that target PDPN can decrease GTPase activity in order to inhibit OSCC cell motility and growth. As shown in Figure 4, neither NZ-1 nor MASL appeared to decrease RhoA or Rac1 GTPase activity at concentrations that inhibit OSCC cell growth or motility. Indeed, instead of decreasing RhoA and Rac1, these reagents seemed to cause a slight increase in these GTPase activities. However, in contrast to RhoA and Rac1, both NZ-1 and MASL appeared to decrease Cdc42 GTPase activity (Figure 4). These data suggest that both reagents may interfere with GTPase control of directional movement, as opposed to mechanisms directing the formation of protractions and protrusions, to inhibit cell migration, even at nontoxic concentrations (e.g. 770 nM) .
Figure 3: Reagents that target PDPN can decrease OSCC cell migration and viability. (a) Wound healing migration assays were performed on confluent OSCC monolayers treated with concentrations of NZ-1 or MASL as indicated. Data are shown as the number of cells that migrated into a 200 x 300 micron area along the center of the wound in 18 hours (mean+SEM, n=5). (b) NZ-1 and MASL toxicity was evaluated by Trypan blue staining of cells treated with NZ-1 or MASL for 24 hours and quantitated as the number of living cells in a 3 mm2 field (mean+SEM, n=5).
Figure 4: Effects of reagents that target PDPN on GTPase activity. Active RhoA, Rac1, and Cdc42 GTPase was detected in HSC-2 cells treated with 0 nM, 770 nM, and 2310 nM NZ-1 or MASL as indicated. Data are shown as percent control untreated cells (mean+SEM, n=3).
NZ-1 and MASL affect OSCC cell viability without inducing apoptotic caspase activation
Effects of NZ-1 and MASL on OSCC cell morphology suggest that these reagents caused necrotic cell death as seen in Figure 5. Although some membrane blebbing was observed, both reagents caused morphological changes indicative of necrosis in HSC-2 and HSC-4 cells. HSQ-89 cells did not exhibit notable changes in morphology, which may be expected from reduced sensitivity to NZ-1 or, particularly, MASL as shown in Figure 3.
Figure 5: Effects of NZ-1 and MASLon OSCC cell morphology. OSCC cells were treated with 2310 nM NZ-1 or MASL for 24 hours and examined by microscopy as indicated (bar = 100 microns).
Effects on morphology suggest that NZ-1 and MASL utilize similar mechanisms to inhibit cell growth, but that cells can react differently to these effects. For example, both compounds induced some membrane blebbing of HSC-2 cells, but not HSC-4 cells. Effects of NZ-1 and MASL on caspase 8 and PARP cleavage were evaluated to further elucidate mechanisms behind their cytotoxicity. As shown in Figure 6, NZ-1 and MASL treated cells did not display significant levels of caspase 8 cleavage in response to these compounds. While some PARP cleavage was seen in HSC-2 cells treated with MASL, this was not found in NZ-1 treated HSC-2 cells or in the other cell lines treated with either reagent (Figure 6). These data suggest that caspase activation was not essential for NZ-1 or MASL toxicity.
Figure 6: NZ-1 and MASL do not induce caspase or PARP cleavage in OSCC cells. (a) PARP, Caspase 8, and GAPDH were examined by Western blotting of protein from OSCC cells treated for 24 hours with 0 nM (control) or 2310 nM NZ-1 or MASL as indicated. (b) Signal was quantitated by image densitometry and shown as the percent of cleaved PARP and Caspase 8 compared to total PARP and Caspase 8, respectively (mean+SEM, n=3).
The pan-caspase blocker Z-VAD-FMK and the mitochondrial membrane permeability transition blocker cyclosporin A were used to further investigate mechanisms underlying MASL and NZ-1 toxicity in HSC-2 and HSC-4 cells. As shown in Figure 7, Z-VAD-FMK did not protect either cell line from MASL or NZ-1 toxicity. In contrast, cyclosporin A decreased toxicity of NZ-1 and MASL by several fold in both cell lines (p<0.0004 by t-test). Taken together, these data indicate that NZ-1 and MASL induce mitochondrial membrane permeability transition to kill OSCC cells by caspase independent nonapoptotic necrosis.
Figure 7: Mitochondrial membrane permeability transition inhibition protects cells from NZ-1 and MASL toxicity, while caspase inhibition does not. The effects of the pan-caspase blocker Z-VAD-FMK and the mitochondrial membrane permeability transition blocker cyclosporin A were examined on HSC-2 and HSC-4 cells treated with 2310 nM NZ-1 or MASL as indicated. Data are shown as percent of cells killed (mean+SEM, n=6).
NZ-1 and MASL display different OSCC cell binding dynamics
As shown in Figure 8a, MASL associated with the plasma membrane after only 2 minutes of exposure on HSC-2 cells. In contrast, NZ-1 was not found to associate with these cells, even after prolonged incubation periods of several hours. Immunofluorescence analysis, shown in Figure 8b and Supplemental Figure 3, found that MASL and PDPN associated with each other on the plasma membrane of these cells. Thus, MASL targeted PDPN on OSCC cells with a surprising efficiency that was not exhibited by the NZ-1 monoclonal antibody.
Figure 8: NZ-1 and MASL exhibit different OSCC cell binding dynamics. (a) HSC-2 cells were incubated with fluorescently labeled MASL or NZ-1 for 2 minutes and examined by confocal microscopy. MASL bound to cell membranes, while NZ-1 did not. (b) Colocalization of MASL and PDPN is evident by confocal microscopy. Bars = 50 microns.
MASL inhibits tumor cell invasion in zebrafish embryos
Zebrafish embryos provide a useful model to visualize tumor cell invasion and metastasis in living animals at the single cell level [69, 70]. We used this model to examine the effects of MASL on OSCC tumor cell dissemination. B16 melanoma cells were included in this study since previous reports indicate that MASL can inhibit their tumorigenesis in mice . As shown in Figure 9, 770 nM MASL inhibited melanoma and OSCC tumor cell dissemination in this system by about 30%. This effect was significant, with p values below 0.001 and 0.05 for melanoma and OSCC cells by t-test, respectively.
Figure 9: MASL inhibits melanoma and OSCC cell metastasis in zebrafish embryos. (top) DiI labeled B16 melanoma and HSC-2 OSCC cells were implanted into the perivitelline cavity of zebrafish embryos grown with or without 770 nM MASL as indicated. Tumor cells (red) and blood vessels (green) were visualized after 3 days of growth. (bottom) Metastasis was quantified as the number of tumor cells that moved anterior to the anal opening (indicated by white arrows). Data are shown as mean+SEM. Single and triple asterisks indicate p<0.05 and p<0.001 (n≥20).
PDPN has emerged as a functionally relevant cancer biomarker and chemotherapeutic target [37, 71]. PDPN is necessary and sufficient to increase tumor cell migration. Oncogenic kinases and PDPN expression vectors augment cell migration [34, 72] and, conversely, agents including siRNA constructs that decrease PDPN expression inhibit cell migration [34, 61, 73]. This has been shown for a variety of cell types including nontransformed and Src transformed cells [34, 72], melanoma , and OSCC cells [73-75].
Indeed, PDPN signaling promotes invasion and metastasis of many types of cancer cells . In particular, increased PDPN expression correlates with the aggressive potential of OSCC cells . These cancer cells are remarkably resistant to currently available chemotherapy treatments [7, 11, 77]. PDPN could serve as a target for more effective treatments to improve outcomes in this patient population. Here, we evaluated how an antibody and lectin that target PDPN affect OSCC cell growth and motility.
Evaluation of cell lines in this study confirmed that PDPN expression correlates with OSCC cell motility. These findings are consistent with PDPN increasing cell migration. It has become very clear that PDPN acts as an important effector of signaling events that underlie cancer progression. Thus, PDPN may present an opportunity to interrupt oncogenic signaling cascades that induce its expression such as those initiated by a number of tumor promoters including Ras [35, 36], FGF/BMP , Src , EGF , and TGFβ [79, 80].
Quantitation of the effects of NZ-1 and MASL on OSCC cell growth and migration indicate that these compounds inhibit cell migration prior to initiating cytotoxicity. For example, MASL completely inhibits OSCC motility at 770 nM, but requires higher concentrations of over 2 µM to effectively inhibit cell viability. These studies also indicate that NZ-1 and MASL induce mitochondrial membrane permeability transition to kill OSCC cells by caspase independent nonapoptotic necrosis. Many cancer cells contain mutations that enable them to migrate and evade caspase mediated apoptosis . Thus, reagents that target PDPN may provide a way to induce caspase independent necrosis in otherwise resistant human OSCC cells.
Although NZ-1 and MASL showed similar effects on cells, they displayed differences in cell binding dynamics. Effects of antibody binding to the PDPN receptor should be considered. For example, perhaps, antibody binding may stimulate PDPN cleavage (e.g. by calpain  or presenilin ) on the membrane of living cells. These results also suggest that cytotoxic effects of NZ-1 and MASL result from signaling events initiated at the plasma membrane since internalization of these compounds into PDPN expressing OSCC cells was not observed.
Human papillomavirus (HPV) infection is considered a risk factor for OSCC. However, OSCC HPV status is highly variable, and is associated with a variety of factors including geographic area and prevalence of other risk factors . We found all cases evaluated in this study to be HPV negative (Supplemental Figure 4). In contrast to HPV, PDPN expression in these samples appears as a functionally relevant biomarker leading to OSCC motility.
In addition to cancer cells themselves, PDPN expression in cancer associated fibroblasts has been associated with tumor aggression and poor clinical outcomes . This has been found in a variety of cancers including mammary carcinoma [86, 87], melanoma , lung squamous cell carcinoma , esophageal adenocarcinoma , and OSCC . Interestingly, human HSC-2 cells form tumors that express PDPN in mice, and also induce PDPN expression in infiltrating mouse cancer associate fibroblasts within the stroma of the tumor as shown in Figure 10. These data are consistent with recent findings that cancer associated fibroblasts express PDPN to promote the motility and survival of neighboring tumor cells .
Antibodies against PDPN can be used to inhibit tumor progression [44-47]. However, in vivo antibody administration is challenging [48-50]. Unlike antibodies, lectins are resistant to gastrointestinal proteolysis [92-94], and can be taken orally to treat cancer [56, 93, 95]. In addition to carbohydrate modifications, lectin interactions are guided by amino acid residues of their target receptor proteins. Previous studies have shown that MASL associates with PDPN on the membrane of melanoma cells . This study found that MASL can target PDPN on OSCC cells with remarkable dynamics, exceeding that of NZ-1 antibody which binds to PDPN with a dissociation constant of less than 1 nM [64, 96].
PDPN has emerged as a clear target for oral cancers and precancerous lesions [97, 98]. Previous studies demonstrate that MASL can survive digestion and enter the circulatory system to inhibit tumor progression in mammals . We show here that MASL can target PDPN to inhibit OSCC cell growth and motility. However, targeting of MASL to other sialic acid modified receptors on cancer cells cannot be ruled out. Future studies should investigate this possibility. Interestingly, Maackia amurensis has been used for many centuries as a medicinal plant to treat ailments including cancer [99-103]. This work sheds light on potential mechanisms that may be exploited to expand our arsenal of targeted cancer treatments, particularly agents that can be administered orally.
Figure 10: PDPN expression in human OSCC cells and infiltrating mouse fibroblasts in xenograft tumors. Tumors from HSC-2 cells were examined with antisera specific for human (D2-40) and mouse (8.1.1) PDPN by immunohistochemistry as indicated.
Evaluation of cell growth and migration
HSC-2, HSC-4, and HSQ-89 cells have been previously described , and were maintained in DMEM (Hyclone SH30021) supplemented with 25 mM HEPES (Hyclone SH30237) and FBS (Seradigm 1400-500) at 37oC in 5% CO2 and 100% humidity. Effects of reagents on cell viability were measured by plating cells at 12% confluence and growing overnight on standard 12 well tissue culture plates (Cyto One CC7682-7512), treating for 24 hours with MASL (Sentrimed) or NZ-1 (prepared as described [46, 53, 104, 105]), and counting cells after staining with Trypan blue. For wound healing migration assays, confluent cell monolayers were treated for 24 hours with MASL or NZ-1, scratched, and migration was quantitated as the number of cells that entered a 200 x 300 micron area in the center of the wound at 18 hours as previously described [61, 72].
DNA was extracted and analyzed by a proprietary HPV Type-Detect 2.0 Bio-Plex diagnostic analysis (Medical Diagnostic Laboratories, Hamilton, NJ) that was designed to detect HPV subtypes 6, 11, 16, 18, 31, 33, 35, 39, 42, 43, 44, 45, 51, 52, 56, 58, 59, 66, and 68. An internal amplification control was included for all samples to verify successful extraction and a lack of PCR inhibitors in the original specimen. Reactions also included negative template controls to calculate CT values above background as well as HPV-type specific DNA and allele specific primer extension (ASPE) positive controls to demonstrate overall assay success. Results for HPV-16 and HPV-18 were also confirmed by a proprietary multiplex real-time PCR assay (Medical Diagnostic Laboratories, Hamilton, NJ) interpreted with Rotor-Gene software (Bio-Rad, Hercules, CA).
Surgical specimens were fixed in 10% formalin in PBS, paraffin embedded, sectioned (4 microns), and processed for hematoxylin/eosin staining and immunohistochemistry with 8.1.1 and D2-40 monoclonal antibodies (Dako) to detect mouse and human PDPN, respectively, as described [61, 106, 107]. OSCC cells were cultured in chamber slides (Lab-Tek 177445), fixed in 10% formalin, and processed for immunohistochemistry as described above. For mouse xenograft studies, 1 million HSC-2 cells were injected into the left flank of immunodeficient NOD scid gamma mice (Jackson Labs 005557) and allowed to form tumors which were excised and examined by immunohistochemistry. Human and mouse experimental protocols were approved by the University Institutional Review Board (study ID Pro2012001544) and Institutional Animal Care and Use Committee (APR 10579), respectively.
Live cell imaging and immunofluorescence studies
Live cell imaging was performed on HSC-2 cells cultured on 35mm poly-D-lysine–coated glass bottom culture dishes (MatTek Corp., P35GC-1.5-14-C). Nuclei were stained with 5 µg/ml of Hoechst 33352 (Life Technologies, H1399). Cells were rinsed with PBS, incubated with 200 µg/ml MASL conjugated with red fluorescent dye (Thermo scientific Dylight 594, 53044) or 200 µg/ml NZ-1 conjugated to green fluorescent dye (Thermo scientific DyLight 488, 53024) for 2 minutes, rinsed thrice with PBS, and fed media. Images were immediately obtained on a Zeiss Axiovert microscope as described .
Immunofluorescence was performed on HSC-2 cells cultured on 35mm poly-D-lysine–coated glass bottom culture dishes (MatTek Corp., P35GC-1.5-14-C), fixed with 2% paraformaldehyde (PFA) in DPBS (Life Technologies, 14040-091) for 5 minutes at 4°C, rinsed with cold 1% PFA, air-dried, and rinsed again with cold DPBS. Cells were then treated with D2-40 PDPN antibody (Dako, M3619) at 1.3 µg/mL for 3 hours, washed, and then labeled with goat anti-mouse IgG conjugated to Alexa Fluor 488 (Life Technologies, A-11001) at 20 µg/mL for 1.5 hours. Cells were then rinsed with DPBS and treated with MASL conjugated with red fluorescent dye (Thermo scientific Dylight 594, 53044) at 0.4 mg/mL for 5 minutes. Nuclei were stained with Hoechst 33352 (Life Technologies, H1399). Images were obtained on a Zeiss Axiovert microscope as described .
Western blotting and GTPase analysis
Western blotting was performed as described previously [61, 72]. Briefly, protein was resolved by SDS-PAGE, transferred to Immobilon-P membranes (Millipore IH1079562), and incubated with antisera specific for PDPN (NZ-1), PARP (Cell Signaling Technology 9542), Caspase 8 (Cell Signaling Technology 9746), or GAPDH (Santa Cruz Biotechnology A1978). Primary antiserum was recognized by appropriate secondary antiserum conjugated to horseradish peroxidase and detected using enhanced chemiluminescence (Thermo Scientific 32106). After blotting, membranes were stained with India ink to verify equal loading and transfer.
Active GTPase was detected in OSCC cells as described . Briefly, HSC-2 cells were grown to 60-70% confluence, treated with 0 nM, 770 nM, and 2310 nM NZ-1 or MASL for 24 hours, and processed to evaluate RhoA, Rac1, and Cdc42 activity using G-LISA kits BK124-S, BK128-S, and BK127-S, respectively, according to manufacturer’s instructions (Cytoskeleton, Inc.).
Utilization of caspase and mitochondrial membrane permeability transition blockers
The Z-VAD-FMK pan-caspase blocker and cyclosporin A mitochondrial membrane permeability transition blocker were used as previously described [110-112]. Briefly, cells were grown to 40% confluence in standard culture dishes, washed and incubated for 1.5 hours with 10 µM Z-VAD-FMK (Calbiochem 219007) or 100 nM cyclosporin A (Calbiochem 239835) prior to the addition of NZ-1 or MASL, incubated for an additional 16 hours, released from the plates with trypsin, washed and resuspended in PBS with 5 mM propidium iodide for 5 minutes, pelleted, and resuspended in PBS. The percentage of viable cells was determined using a Cellometer (Nexelom, Lawrence, MA), as the ratio of the number of fluorescent cells (propidium iodide positive) to total cells.
Zebrafish tumor cell dissemination assay
The metastatic potential of human squamous cell carcinoma (HSC-2) or melanoma (B16) cells were tested by zebrafish tumor xenograft cell dissemination assays as described [69, 70]. Briefly, tumor cells were labeled with DiI (Invitrogen 3899), suspended at 100 million cells/mL, and injected into 2 day old transgenic fli1a:EGFP embryos (ZIRC, Eugene, Oregon) anesthetized with 0.04% MS-222 (Sigma E10521) at 300-500 cells/embryo. Correct implantation was verified by fluorescence microscopy (Nikon SMZ1500 with NIS Elements F software) shortly after injection, and embryos in which cells were already present in circulation were removed. Embryos were then incubated for 3 days in PTU-supplemented E3 water without methylene blue (Sigma P7629) with and without 770 nM MASL (Sentrimed). Embryos were then anesthetized and disseminated tumor cells were counted as the number of fluorescent DiI labeled cells anterior to the anal opening at 5 days post fertilization. Three independent experiments were done with similar results.
Statistical analyses were performed with GraphPad Prism version 6.
This work was supported in part by funding from the Osteopathic Heritage Foundation, Northarvest Bean Growers Association, New Jersey Health Foundation, and Sentrimed to GSG, the Platform for Drug Discovery, Informatics, and Structural Life Science from the Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan, by Regional Innovation Strategy Support Program from MEXT of Japan, by Grant-in-Aid for Scientific Research from MEXT of Japan to YK, and the New Jersey Health Foundation to AJS.
1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D. Global cancer statistics. CA Cancer JClin. 2011; 61(2):69-90.
2. Johnson NW, Jayasekara P and Amarasinghe AA. Squamous cell carcinoma and precursor lesions of the oral cavity: epidemiology and aetiology. Periodontol2000. 2011; 57(1):19-37.
3. Warnakulasuriya S. Global epidemiology of oral and oropharyngeal cancer. Oral Oncol. 2009; 45(4-5):309-316.
4. Inoue H, Miyazaki Y, Kikuchi K, Yoshida N, Ide F, Ohmori Y, Tomomura A, Sakashita H and Kusama K. Podoplanin expression during dysplasia-carcinoma sequence in the oral cavity. TumourBiol. 2012; 33(1):183-194.
5. Kreppel M, Drebber U, Wedemeyer I, Eich HT, Backhaus T, Zoller JE and Scheer M. Podoplanin expression predicts prognosis in patients with oral squamous cell carcinoma treated with neoadjuvant radiochemotherapy. Oral Oncol. 2011; 47(9):873-878.
6. Shah JP and Gil Z. Current concepts in management of oral cancer--surgery. Oral Oncol. 2009; 45(4-5):394-401.
7. da Silva SD, Hier M, Mlynarek A, Kowalski LP and Alaoui-Jamali MA. Recurrent oral cancer: current and emerging therapeutic approaches. Front Pharmacol. 2012; 3:149.
8. Fan S, Tang QL, Lin YJ, Chen WL, Li JS, Huang ZQ, Yang ZH, Wang YY, Zhang DM, Wang HJ, Dias-Ribeiro E, Cai Q and Wang L. A review of clinical and histological parameters associated with contralateral neck metastases in oral squamous cell carcinoma. IntJOral Sci. 2011; 3(4):180-191.
9. Huang TL, Tsai WL, Chien CY, Lee TF and Fang FM. Quality of life for head and neck cancer patients treated by combined modality therapy: the therapeutic benefit of technological advances in radiotherapy. QualLife Res. 2010; 19(9):1243-1254.
10. Logan RM. Advances in understanding of toxicities of treatment for head and neck cancer. Oral Oncol. 2009; 45(10):844-848.
11. Garraway LA and Janne PA. Circumventing cancer drug resistance in the era of personalized medicine. Cancer Discov. 2012; 2(3):214-226.
12. Rodriguez-Caballero A, Torres-Lagares D, Robles-Garcia M, Pachon-Ibanez J, Gonzalez-Padilla D and Gutierrez-Perez JL. Cancer treatment-induced oral mucositis: a critical review. IntJOral MaxillofacSurg. 2012; 41(2):225-238.
13. Wood ER, Truesdale AT, McDonald OB, Yuan D, Hassell A, Dickerson SH, Ellis B, Pennisi C, Horne E, Lackey K, Alligood KJ, Rusnak DW, Gilmer TM and Shewchuk L. A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Research. 2004; 64(18):6652-6659.
14. Nelson MH and Dolder CR. Lapatinib: a novel dual tyrosine kinase inhibitor with activity in solid tumors. AnnPharmacother. 2006; 40(2):261-269.
15. Bange J, Zwick E and Ullrich A. Molecular targets for breast cancer therapy and prevention. NatMed. 2001; 7(5):548-552.
16. Los M, Roodhart JM and Voest EE. Target practice: lessons from phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer. Oncologist. 2007; 12(4):443-450.
17. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, Ove R, Kies MS, Baselga J, Youssoufian H, Amellal N, Rowinsky EK, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. NEnglJMed. 2006; 354(6):567-578.
18. Robert F, Ezekiel MP, Spencer SA, Meredith RF, Bonner JA, Khazaeli MB, Saleh MN, Carey D, LoBuglio AF, Wheeler RH, Cooper MR and Waksal HW. Phase I study of anti--epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. JClinOncol. 2001; 19(13):3234-3243.
19. Shah NG, Trivedi TI, Tankshali RA, Goswami JA, Shah JS, Jetly DH, Kobawala TP, Patel KC, Shukla SN, Shah PM and Verma RJ. Molecular alterations in oral carcinogenesis: significant risk predictors in malignant transformation and tumor progression. IntJBiolMarkers. 2007; 22(2):132-143.
20. Mascolo M, Siano M, Ilardi G, Russo D, Merolla F, de Rosa G and Staibano S. Epigenetic disregulation in oral cancer. IntJMolSci. 2012; 13(2):2331-2353.
21. da Silva SD, Ferlito A, Takes RP, Brakenhoff RH, Valentin MD, Woolgar JA, Bradford CR, Rodrigo JP, Rinaldo A, Hier MP and Kowalski LP. Advances and applications of oral cancer basic research. Oral Oncol. 2011; 47(9):783-791.
22. Perez-Sayans GM, Suarez-Penaranda JM, Gayoso-Diz P, Barros-Angueira F, Gandara-Rey JM and Garcia-Garcia A. Tissue inhibitor of metalloproteinases in oral squamous cell carcinomas - a therapeutic target? Cancer Lett. 2012; 323(1):11-19.
23. William WN, Jr. Oral premalignant lesions: any progress with systemic therapies? CurrOpinOncol. 2012.
24. Temam S, Kawaguchi H, El Naggar AK, Jelinek J, Tang H, Liu DD, Lang W, Issa JP, Lee JJ and Mao L. Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer. JClinOncol. 2007; 25(16):2164-2170.
25. Funayama A, Cheng J, Maruyama S, Yamazaki M, Kobayashi T, Syafriadi M, Kundu S, Shingaki S, Saito C and Saku T. Enhanced expression of podoplanin in oral carcinomas in situ and squamous cell carcinomas. Pathobiology. 2011; 78(3):171-180.
26. Inoue H, Miyazaki Y, Kikuchi K, Yoshida N, Ide F, Ohmori Y, Tomomura A, Sakashita H and Kusama K. Podoplanin promotes cell migration via the EGF-Src-Cas pathway in oral squamous cell carcinoma cell lines. JOral Sci. 2012; 54(3):241-250.
27. Cueni LN, Hegyi I, Shin JW, Albinger-Hegyi A, Gruber S, Kunstfeld R, Moch H and Detmar M. Tumor lymphangiogenesis and metastasis to lymph nodes induced by cancer cell expression of podoplanin. AmJPathol. 2010; 177(2):1004-1016.
28. Huber GF, Fritzsche FR, Zullig L, Storz M, Graf N, Haerle K, Jochum W, Stoeckli SJ and Moch H. Podoplanin expression correlates with sentinel lymph node metastasis in early squamous cell carcinomas of the oral cavity and oropharynx. IntJCancer. 2011; 129(6):1404-1409.
29. Kreppel M, Scheer M, Drebber U, Ritter L and Zoller JE. Impact of podoplanin expression in oral squamous cell carcinoma: clinical and histopathologic correlations. Virchows Arch. 2010; 456(5):473-482.
30. Martin-Villar E, Scholl FG, Gamallo C, Yurrita MM, Munoz-Guerra M, Cruces J and Quintanilla M. Characterization of human PA2.26 antigen (T1alpha-2, podoplanin), a small membrane mucin induced in oral squamous cell carcinomas. IntJCancer. 2005; 113(6):899-910.
31. Martin-Villar E, Fernandez-Munoz B, Parsons M, Yurrita MM, Megias D, Perez-Gomez E, Jones GE and Quintanilla M. Podoplanin Associates with CD44 to Promote Directional Cell Migration. MolBiolCell. 2010; 21:4387-4399.
32. Deng H, Sambrook PJ and Logan RM. The treatment of oral cancer: an overview for dental professionals. AustDentJ. 2011; 56(3):244-252, 341.
33. Noguti J, De Moura CF, De Jesus GP, Da Silva VH, Hossaka TA, Oshima CT and Ribeiro DA. Metastasis from oral cancer: an overview. Cancer Genomics Proteomics. 2012; 9(5):329-335.
34. Shen Y, Chen CS, Ichikawa H and Goldberg GS. SRC induces podoplanin expression to promote cell migration. JBiolChem. 2010; 285(13):9649-9656.
35. Gandarillas A, Scholl FG, Benito N, Gamallo C and Quintanilla M. Induction of PA2.26, a cell-surface antigen expressed by active fibroblasts, in mouse epidermal keratinocytes during carcinogenesis. MolCarcinog. 1997; 20(1):10-18.
36. Nose K, Saito H and Kuroki T. Isolation of a gene sequence induced later by tumor-promoting 12-O-tetradecanoylphorbol-13-acetate in mouse osteoblastic cells (MC3T3-E1) and expressed constitutively in ras-transformed cells. Cell Growth Differ. 1990; 1(11):511-518.
37. Wicki A and Christofori G. The potential role of podoplanin in tumour invasion. BrJCancer. 2007; 96(1):1-5.
38. Yu Y, Khan J, Khanna C, Helman L, Meltzer PS and Merlino G. Expression profiling identifies the cytoskeletal organizer ezrin and the developmental homeoprotein Six-1 as key metastatic regulators. NatMed. 2004; 10(2):175-181.
39. Wicki A, Lehembre F, Wick N, Hantusch B, Kerjaschki D and Christofori G. Tumor invasion in the absence of epithelial-mesenchymal transition: podoplanin-mediated remodeling of the actin cytoskeleton. Cancer Cell. 2006; 9(4):261-272.
40. Cortez MA, Nicoloso MS, Shimizu M, Rossi S, Gopisetty G, Molina JR, Carlotti C, Jr., Tirapelli D, Neder L, Brassesco MS, Scrideli CA, Tone LG, Georgescu MM, Zhang W, Puduvalli V and Calin GA. miR-29b and miR-125a regulate podoplanin and suppress invasion in glioblastoma. Genes ChromosomesCancer. 2010; 49:981-990.
41. Mumprecht V and Detmar M. Lymphangiogenesis and cancer metastasis. JCell MolMed. 2009; 13(8A):1405-1416.
42. Mohammed RA, Martin SG, Gill MS, Green AR, Paish EC and Ellis IO. Improved methods of detection of lymphovascular invasion demonstrate that it is the predominant method of vascular invasion in breast cancer and has important clinical consequences. AmJSurgPathol. 2007; 31(12):1825-1833.
43. Kunita A, Kashima TG, Morishita Y, Fukayama M, Kato Y, Tsuruo T and Fujita N. The platelet aggregation-inducing factor aggrus/podoplanin promotes pulmonary metastasis. AmJPathol. 2007; 170(4):1337-1347.
44. Chandramohan V, Bao X, Kato Kaneko M, Kato Y, Keir ST, Szafranski SE, Kuan CT, Pastan IH and Bigner DD. Recombinant anti-podoplanin (NZ-1) immunotoxin for the treatment of malignant brain tumors. International journal of cancer Journal international du cancer. 2013; 132(10):2339-2348.
45. Abe S, Morita Y, Kaneko MK, Hanibuchi M, Tsujimoto Y, Goto H, Kakiuchi S, Aono Y, Huang J, Sato S, Kishuku M, Taniguchi Y, Azuma M, Kawazoe K, Sekido Y, Yano S, et al. A novel targeting therapy of malignant mesothelioma using anti-podoplanin antibody. Journal of immunology. 2013; 190(12):6239-6249.
46. Kaneko MK, Kunita A, Abe S, Tsujimoto Y, Fukayama M, Goto K, Sawa Y, Nishioka Y and Kato Y. A chimeric anti-podoplanin antibody suppresses tumor metastasis via neutralization and antibody-dependent cellular cytotoxicity. Cancer Sci. 2012.
47. Nakazawa Y, Sato S, Naito M, Kato Y, Mishima K, Arai H, Tsuruo T and Fujita N. Tetraspanin family member CD9 inhibits Aggrus/podoplanin-induced platelet aggregation and suppresses pulmonary metastasis. Blood. 2008; 112:1730-1739.
48. Bagnyukova T, Serebriiskii IG, Zhou Y, Hopper-Borge EA, Golemis EA and Astsaturov I. Chemotherapy and signaling: How can targeted therapies supercharge cytotoxic agents? Cancer BiolTher. 2010; 10(9).
49. Johnson KA and Brown PH. Drug development for cancer chemoprevention: focus on molecular targets. SeminOncol. 2010; 37(4):345-358.
50. de Bono JS and Ashworth A. Translating cancer research into targeted therapeutics. Nature. 2010; 467(7315):543-549.
51. Cueni LN and Detmar M. Galectin-8 interacts with podoplanin and modulates lymphatic endothelial cell functions. Experimental Cell Research. 2009; 315(10):1715-1723.
52. Christou CM, Pearce AC, Watson AA, Mistry AR, Pollitt AY, Fenton-May AE, Johnson LA, Jackson DG, Watson SP and O’Callaghan CA. Renal cells activate the platelet receptor CLEC-2 through podoplanin. BiochemJ. 2008; 411(1):133-140.
53. Suzuki-Inoue K, Kato Y, Inoue O, Kaneko MK, Mishima K, Yatomi Y, Yamazaki Y, Narimatsu H and Ozaki Y. Involvement of the snake toxin receptor CLEC-2, in podoplanin-mediated platelet activation, by cancer cells. JBiolChem. 2007; 282(36):25993-26001.
54. Witz IP. The involvement of selectins and their ligands in tumor-progression. ImmunolLett. 2006; 104(1-2):89-93.
55. Ingrassia L, Camby I, Lefranc F, Mathieu V, Nshimyumukiza P, Darro F and Kiss R. Anti-galectin compounds as potential anti-cancer drugs. CurrMedChem. 2006; 13(29):3513-3527.
56. Hasan SS, Ashraf GM and Banu N. Galectins - potential targets for cancer therapy. Cancer Lett. 2007; 253(1):25-33.
57. Maenuma K, Yim M, Komatsu K, Hoshino M, Tachiki-Fujioka A, Takahashi K, Hiki Y, Bovin N and Irimura T. A library of mutated Maackia amurensis hemagglutinin distinguishes putative glycoforms of immunoglobulin A1 from IgA nephropathy patients. JProteomeRes. 2009; 8(7):3617-3624.
58. Maenuma K, Yim M, Komatsu K, Hoshino M, Takahashi Y, Bovin N and Irimura T. Use of a library of mutated Maackia amurensis hemagglutinin for profiling the cell lineage and differentiation. Proteomics. 2008; 8(16):3274-3283.
59. Imberty A, Gautier C, Lescar J, Perez S, Wyns L and Loris R. An unusual carbohydrate binding site revealed by the structures of two Maackia amurensis lectins complexed with sialic acid-containing oligosaccharides. JBiolChem. 2000; 275(23):17541-17548.
60. Van Damme EJ, Van Leuven F and Peumans WJ. Isolation, characterization and molecular cloning of the bark lectins from Maackia amurensis. GlycoconjJ. 1997; 14(4):449-456.
61. Ochoa-Alvarez JA, Krishnan H, Shen Y, Acharya NK, Han M, McNulty DE, Hasegawa H, Hyodo T, Senga T, Geng JG, Kosciuk M, Shin SS, Goydos JS, Temiakov D, Nagele RG and Goldberg GS. Plant lectin can target receptors containing sialic Acid, exemplified by podoplanin, to inhibit transformed cell growth and migration. PLoSONE. 2012; 7(7):e41845.
62. Krishnan H, Miller WT and Goldberg GS. SRC points the way to biomarkers and chemotherapeutic targets. Genes Cancer. 2012; 3(5-6):426-435.
63. Kato Y, Kaneko MK, Kunita A, Ito H, Kameyama A, Ogasawara S, Matsuura N, Hasegawa Y, Suzuki-Inoue K, Inoue O, Ozaki Y and Narimatsu H. Molecular analysis of the pathophysiological binding of the platelet aggregation-inducing factor podoplanin to the C-type lectin-like receptor CLEC-2. Cancer Sci. 2008; 99(1):54-61.
64. Kato Y, Vaidyanathan G, Kaneko MK, Mishima K, Srivastava N, Chandramohan V, Pegram C, Keir ST, Kuan CT, Bigner DD and Zalutsky MR. Evaluation of anti-podoplanin rat monoclonal antibody NZ-1 for targeting malignant gliomas. NuclMedBiol. 2010; 37(7):785-794.
65. Ernst A, Hofmann S, Ahmadi R, Becker N, Korshunov A, Engel F, Hartmann C, Felsberg J, Sabel M, Peterziel H, Durchdewald M, Hess J, Barbus S, Campos B, Starzinski-Powitz A, Unterberg A, et al. Genomic and expression profiling of glioblastoma stem cell-like spheroid cultures identifies novel tumor-relevant genes associated with survival. ClinCancer Res. 2009; 15(21):6541-6550.
66. Acton SE, Farrugia AJ, Astarita JL, Mourao-Sa D, Jenkins RP, Nye E, Hooper S, van Blijswijk J, Rogers NC, Snelgrove KJ, Rosewell I, Moita LF, Stamp G, Turley SJ, Sahai E and Reis e Sousa C. Dendritic cells control fibroblastic reticular network tension and lymph node expansion. Nature. 2014; 514(7523):498-502.
67. Acton SE, Astarita JL, Malhotra D, Lukacs-Kornek V, Franz B, Hess PR, Jakus Z, Kuligowski M, Fletcher AL, Elpek KG, Bellemare-Pelletier A, Sceats L, Reynoso ED, Gonzalez SF, Graham DB, Chang J, et al. Podoplanin-Rich Stromal Networks Induce Dendritic Cell Motility via Activation of the C-type Lectin Receptor CLEC-2. Immunity. 2012.
68. Raftopoulou M and Hall A. Cell migration: Rho GTPases lead the way. Developmental biology. 2004; 265(1):23-32.
69. Rouhi P, Jensen LD, Cao Z, Hosaka K, Lanne T, Wahlberg E, Steffensen JF and Cao Y. Hypoxia-induced metastasis model in embryonic zebrafish. Nature protocols. 2010; 5(12):1911-1918.
70. Lee SL, Rouhi P, Dahl Jensen L, Zhang D, Ji H, Hauptmann G, Ingham P and Cao Y. Hypoxia-induced pathological angiogenesis mediates tumor cell dissemination, invasion, and metastasis in a zebrafish tumor model. Proceedings of the National Academy of Sciences of the United States of America. 2009; 106(46):19485-19490.
71. Astarita JL, Acton SE and Turley SJ. Podoplanin: emerging functions in development, the immune system, and cancer. Front Immunol. 2012; 3:283.
72. Krishnan H, Ochoa-Alvarez JA, Shen Y, Nevel E, Lakshminarayanan M, Williams MC, Ramirez MI, Miller WT and Goldberg GS. Serines in the intracellular tail of podoplanin (PDPN) regulate cell motility. The Journal of biological chemistry. 2013; 288(17):12215-12221.
73. Fujii M, Honma M, Takahashi H, Ishida-Yamamoto A and Iizuka H. Intercellular contact augments epidermal growth factor receptor (EGFR) and signal transducer and activator of transcription 3 (STAT3)-activation which increases podoplanin-expression in order to promote squamous cell carcinoma motility. Cellular signalling. 2013; 25(4):760-765.
74. Honma M, Minami-Hori M, Takahashi H and Iizuka H. Podoplanin expression in wound and hyperproliferative psoriatic epidermis: Regulation by TGF-beta and STAT-3 activating cytokines, IFN-gamma, IL-6, and IL-22. JDermatolSci. 2012; 65(2):134-140.
75. Tsuneki M, Yamazaki M, Maruyama S, Cheng J and Saku T. Podoplanin-mediated cell adhesion through extracellular matrix in oral squamous cell carcinoma. Lab Invest. 2013; 93(8):921-932.
76. Swain N, Kumar SV, Routray S, Pathak J and Patel S. Podoplanin-a novel marker in oral carcinogenesis. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 2014.
77. Mazeron R, Tao Y, Lusinchi A and Bourhis J. Current concepts of management in radiotherapy for head and neck squamous-cell cancer. Oral Oncol. 2009; 45(4-5):402-408.
78. Sailer MH, Gerber A, Tostado C, Hutter G, Cordier D, Mariani L and Ritz MF. Non-invasive neural stem cells become invasive in vitro by combined FGF2 and BMP4 signaling. J Cell Sci. 2013; 126(Pt 16):3533-3540.
79. Hwang YS, Park KK and Chung WY. Stromal transforming growth factor-beta 1 is crucial for reinforcing the invasive potential of low invasive cancer. Archives of oral biology. 2014; 59(7):687-694.
80. Hwang YS, Zhang X, Park KK and Chung WY. Functional invadopodia formation through stabilization of the PDPN transcript by IMP-3 and cancer-stromal crosstalk for PDPN expression. Carcinogenesis. 2012.
81. Hanahan D and Weinberg RA. The hallmarks of cancer. Cell. 2000; 100(1):57-70.
82. Martin-Villar E, Yurrita MM, Fernandez-Munoz B, Quintanilla M and Renart J. Regulation of podoplanin/PA2.26 antigen expression in tumour cells. Involvement of calpain-mediated proteolysis. IntJBiochemCell Biol. 2009; 41(6):1421-1429.
83. Yurrita MM, Fernandez-Munoz B, Del Castillo G, Martin-Villar E, Renart J and Quintanilla M. Podoplanin is a substrate of presenilin-1/gamma-secretase. The international journal of biochemistry & cell biology. 2014; 46:68-75.
84. Zaravinos A. An updated overview of HPV-associated head and neck carcinomas. Oncotarget. 2014; 5(12):3956-3969.
85. Pula B, Witkiewicz W, Dziegiel P and Podhorska-Okolow M. Significance of podoplanin expression in cancer-associated fibroblasts: a comprehensive review. International journal of oncology. 2013; 42(6):1849-1857.
86. Niemiec JA, Adamczyk A, Ambicka A, Mucha-Malecka A, W MW and Rys J. Triple-negative, basal marker-expressing, and high-grade breast carcinomas are characterized by high lymphatic vessel density and the expression of podoplanin in stromal fibroblasts. Applied immunohistochemistry & molecular morphology : AIMM / official publication of the Society for Applied Immunohistochemistry. 2014; 22(1):10-16.
87. Pula B, Jethon A, Piotrowska A, Gomulkiewicz A, Owczarek T, Calik J, Wojnar A, Witkiewicz W, Rys J, Ugorski M, Dziegiel P and Podhorska-Okolow M. Podoplanin expression by cancer-associated fibroblasts predicts poor outcome in invasive ductal breast carcinoma. Histopathology. 2011; 59(6):1249-1260.
88. Kan S, Konishi E, Arita T, Ikemoto C, Takenaka H, Yanagisawa A, Katoh N and Asai J. Podoplanin expression in cancer-associated fibroblasts predicts aggressive behavior in melanoma. Journal of cutaneous pathology. 2014.
89. Ono S, Ishii G, Nagai K, Takuwa T, Yoshida J, Nishimura M, Hishida T, Aokage K, Fujii S, Ikeda N and Ochiai A. Podoplanin-positive cancer-associated fibroblasts could have prognostic value independent of cancer cell phenotype in stage I lung squamous cell carcinoma: usefulness of combining analysis of both cancer cell phenotype and cancer-associated fibroblast phenotype. Chest. 2013; 143(4):963-970.
90. Schoppmann SF, Jesch B, Riegler MF, Maroske F, Schwameis K, Jomrich G and Birner P. Podoplanin expressing cancer associated fibroblasts are associated with unfavourable prognosis in adenocarcinoma of the esophagus. Clinical & experimental metastasis. 2013; 30(4):441-446.
91. Inoue H, Tsuchiya H, Miyazaki Y, Kikuchi K, Ide F, Sakashita H and Kusama K. Podoplanin expressing cancer-associated fibroblasts in oral cancer. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 2014.
92. Pryme IF, Bardocz S, Pusztai A and Ewen SW. Dietary mistletoe lectin supplementation and reduced growth of a murine non-Hodgkin lymphoma. HistolHistopathol. 2002; 17(1):261-271.
93. Pusztai A, Bardocz S and Ewen SW. Uses of plant lectins in bioscience and biomedicine. Front Biosci. 2008; 13:1130-1140.
94. Wang Q, Yu LG, Campbell BJ, Milton JD and Rhodes JM. Identification of intact peanut lectin in peripheral venous blood. Lancet. 1998; 352(9143):1831-1832.
95. Pryme IF, Bardocz S, Pusztai A and Ewen SW. Suppression of growth of tumour cell lines in vitro and tumours in vivo by mistletoe lectins. HistolHistopathol. 2006; 21(3):285-299.
96. Ogasawara S, Kaneko MK, Price JE and Kato Y. Characterization of anti-podoplanin monoclonal antibodies: critical epitopes for neutralizing the interaction between podoplanin and CLEC-2. Hybridoma (Larchmt). 2008; 27(4):259-267.
97. Kawaguchi H, El Naggar AK, Papadimitrakopoulou V, Ren H, Fan YH, Feng L, Lee JJ, Kim E, Hong WK, Lippman SM and Mao L. Podoplanin: a novel marker for oral cancer risk in patients with oral premalignancy. JClinOncol. 2008; 26(3):354-360.
98. Yuan P, Temam S, El Naggar A, Zhou X, Liu DD, Lee JJ and Mao L. Overexpression of podoplanin in oral cancer and its association with poor clinical outcome. Cancer. 2006; 107(3):563-569.
99. Fedoreev SA, Kulish NI, Glebko LI, Pokushalova TV, Veselova MV, Saratikov AS, Vengerovskii AI and Chuchalin VS. Maksar: A preparation based on amur maackia. Pharmaceutical Chemistry Journal. 2010; 38(11):605-610.
100. Li JF, Cui Z and Zhang FL. (2006). Research progress in the chemical constituents and pharmacological activities of Maackia. pp. 541-545.
101. Li X, Wang D, Xia MY, Wang ZH, Wang WN and Cui Z. Cytotoxic prenylated flavonoids from the stem bark of Maackia amurensis. ChemPharmBull(Tokyo). 2009; 57(3):302-306.
102. Luo J, Liang G and Jiang S. Study on extraction and hepatoprotective function of isoflavones from callus cultures of Maackia Amurensis. Food Science. 2003; 24(10):139-142.
103. Li S. (1593). Bencao Gangmu (A Materia Medica, Arranged according to Drug Descriptions and Technical Aspects) (China: Ming Dynasty).
104. Kato Y, Kaneko MK, Kuno A, Uchiyama N, Amano K, Chiba Y, Hasegawa Y, Hirabayashi J, Narimatsu H, Mishima K and Osawa M. Inhibition of tumor cell-induced platelet aggregation using a novel anti-podoplanin antibody reacting with its platelet-aggregation-stimulating domain. BiochemBiophysResCommun. 2006; 349(4):1301-1307.
105. Kato Y and Kaneko MK. A Cancer-specific Monoclonal Antibody Recognizes the Aberrantly Glycosylated Podoplanin. Scientific reports. 2014; 4:5924.
106. Li X, Jia Z, Shen Y, Ichikawa H, Jarvik J, Nagele RG and Goldberg GS. Coordinate suppression of Sdpr and Fhl1 expression in tumors of the breast, kidney, and prostate. Cancer Sci. 2008; 99(7):1326-1333.
107. Shen Y, Jia Z, Nagele RG, Ichikawa H and Goldberg GS. SRC uses Cas to suppress Fhl1 in order to promote nonanchored growth and migration of tumor cells. Cancer Research. 2006; 66(3):1543-1552.
108. Shen Y, Khusial PR, Li X, Ichikawa H, Moreno AP and Goldberg GS. SRC utilizes Cas to block gap junctional communication mediated by connexin43. J Biol Chem. 2007; 282(26):18914-18921.
109. Ito S, Ishii G, Hoshino A, Hashimoto H, Neri S, Kuwata T, Higashi M, Nagai K and Ochiai A. Tumor promoting effect of podoplanin-positive fibroblasts is mediated by enhanced RhoA activity. BiochemBiophysResCommun. 2012; 422(1):194-199.
110. Snyder JW, Pastorino JG, Attie AM and Farber JL. Protection by cyclosporin A of cultured hepatocytes from the toxic consequences of the loss of mitochondrial energization produced by 1-methyl-4-phenylpyridinium. Biochemical pharmacology. 1992; 44(4):833-835.
111. Pastorino JG, Snyder JW, Serroni A, Hoek JB and Farber JL. Cyclosporin and carnitine prevent the anoxic death of cultured hepatocytes by inhibiting the mitochondrial permeability transition. The Journal of biological chemistry. 1993; 268(19):13791-13798.
112. Pastorino JG and Shulga N. Tumor necrosis factor-alpha can provoke cleavage and activation of sterol regulatory element-binding protein in ethanol-exposed cells via a caspase-dependent pathway that is cholesterol insensitive. JBiolChem. 2008; 283(37):25638-25649.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.